Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy And Safety Study Of Tanezumab As Add-On Therapy To Opioid Medication In Patients With Pain Due To Bone Metastases.

Trial Profile

Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy And Safety Study Of Tanezumab As Add-On Therapy To Opioid Medication In Patients With Pain Due To Bone Metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Tanezumab (Primary) ; Opioid analgesics
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2012 Planned number of patients changed from 58 to 60 as reported by European Clinical Trials Database (Parent trial: EudraCT2008-005181-31).
    • 04 Jul 2012 Lead trial investigator identified as reported by Clinical Trials Registry - India (Parent trial: CTRI2011-05-001754).
    • 13 Apr 2012 Actual end date Feb 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top